Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 920

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 920
---
1 to BLAC’s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on February 15, 2023)                                                                                                          |
| 3.2*    |     | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Bellevue Life Sciences Acquisition Corp. dated as of November 9, 2023 (incorporated by reference to Exhibit 3.1 to BLAC’s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on November 15, 2023) |
| 3.3*    |     | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Bellevue Life Sciences Acquisition Corp. dated as of February 9, 2024 (incorporated by reference to Exhibit 3.1 to BLAC’s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on February 13, 2024) |
| 3.4*    |     | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Bellevue Life Sciences Acquisition Corp. dated as of May 14, 2024 (incorporated by reference to Exhibit 3.1 to BLAC’s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on May 14, 2024)          |
| 3.5*    |     | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Bellevue Life Sciences Acquisition Corp dated as of November 12, 2024 (incorporated by reference to Exhibit 3.1 to BLAC’s Current Report on Form 8-K (File No. 001-41390) filed with the SEC on November 12, 2024) |
| 3.6*    |     | By-Laws (incorporated by reference to Exhibit 3.2 to Amendment No. 1 to BLAC’s Form S-1 (File No. 333-264597) filed with the SEC on May 10, 2022)                                                                                                                                                       |
| 3.7**   |     | Form of Second Amended and Restated Certificate of Incorporation of Bellevue Life Sciences Acquisition Corp., to be effective immediately after the closing of the Business Combination (attached as Annex F to the proxy statement/prospectus